Summit Therapeutics to Host R&D Day 7 October 2019

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

Summit Therapeutics to Host R&D Day 7 October 2019

Oxford, UK, and Cambridge, MA, US, 25 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that it will host a research and development day for investors and media on 7 October 2019 from 8am-12pm EDT in New York City.

The event will feature leading experts: Dr Casey Theriot, of North Carolina State University, on the role of the microbiome in C. difficile infection (‘CDI’) and Dr Kevin Garey, of the University of Houston, on the economic and patient impact of CDI. Summit’s management team will provide insight on the Company’s precision antibiotic ridinilazole as a potential front-line treatment for CDI, which is currently in Phase 3 clinical trials. In addition, management will discuss the Company’s Discuva Platform, aimed at discovering novel class, targeted antibiotics for serious infectious diseases.

A live webcast of the event will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the conclusion of the live presentation.

For further details, or to request an invitation, email [email protected].

About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit
Glyn Edwards / Richard Pye (UK office)	Tel:	44 (0)1235 443 951
Michelle Avery (US office)		+1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser)	Tel:	+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker)	Tel:	+44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint Broker)	Tel:	+44 (0)20 7332 2500
Phil Walker / Dominic Wilson
MSL Group (US)	Tel:	+1 781 684 6652
Erin Anthoine		[email protected]
Consilium Strategic Communications (UK)	Tel:	+44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Sukaina Virji		[email protected]
Lindsey Neville

-END-

Source: Summit Therapeutics plc

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• The Housing Market's Supply Problem Has an Assembly-Line Answer, and an Agreement Covering 1,500-Homes Will Put It to the Test
• OroCarbo reserves 12 SYNOCA® C-iC units from Haffner Energy, generating up to €30M in potential revenue
• Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers